SYDNEY, Australia and LISLE, Ill., Sept. 25 /PRNewswire/ -- AtCor Medical Holdings Limited , the developer and marketer of the SphygmoCor system which measures central blood pressure non-invasively, today announced that Mr. Duncan Ross will become Chief Executive Officer of the company at the annual general meeting on 9 November 2006.
Mr Ross is currently President and CEO of AtCor’s North American business and has over 23 years experience in the clinical diagnostics and life sciences device industry. Mr. Ross began his career with the American Hospital Supply Corporation and Baxter International. Prior to joining AtCor, Mr. Ross was President of Apogent Technologies’ and Fisher Scientific Products’ laboratory equipment group, the number two supplier in the global $2.8 billion laboratory equipment market. Mr. Ross is a Summa Cum Laude graduate of Babson College.
Mr. Ross will succeed Mr. Ross Harricks, the co-founder of AtCor, who will remain an executive director of the company, focusing on corporate and technology development.
Mr. Donal O’Dwyer, chairman of AtCor, said: “I am delighted Duncan Ross has agreed to lead the company as we develop the US market for AtCor’s SphygmoCor system. His enthusiasm for SphygmoCor, based on his extensive knowledge of the medical devices industry, will be a great asset in building sales to the estimated US$1bn pharmaceutical and clinical practice market.
“I would like to thank Ross Harricks for his vision, determination and energy during the company’s early stages and through our recent Initial Public Offering. AtCor’s future success will be a great tribute to his hard work.”
Mr. Harricks said: “It has always been our intention to appoint a CEO based in the USA. Duncan Ross has impressed us greatly since he joined AtCor in May, and I am confident he has the skills to capitalise on the company’s achievements to date and take advantage of the market opportunities for SphygmoCor, both in the US and in Europe.”
Mr. Ross said: “I am very excited by the potential of the SphygmoCor system. The clinical information and indices available through this relatively inexpensive, non-invasive technology have the ability to transform the early diagnosis, intervention and ongoing management of cardiovascular disease.”
AtCor Medical Holdings Limited
CONTACT: Donal O’Dwyer, 0407 535200, or USA, Doug Kurschinski,+1-630-799-8215, or d.kurschinski@atcormedical.com , or Media enquiries toLarry Watts, Director- Marketing Services, +1-630-799-8219, all of AtCorMedical
Web site: http://www.atcormedical.com/
